Teladoc price target lowered to $17 from $18 at Wells Fargo

Wells Fargo lowered the firm’s price target on Teladoc to $17 from $18 and keeps an Equal Weight rating on the shares. While Teladoc continues to make progress on margins, the company’s latest long-term revenue growth outlook drives further estimate revisions and makes it difficult to justify a premium multiple, the firm argues.